论文部分内容阅读
采用Ｓ－Ｐ免疫组化技术检测３８例原发和复发膀胱移行细胞癌病人的５７块石蜡包埋组织块（其中复发二次以上病人２４例，５年以上未复发者９例，有转移或死亡者５例）的突变型Ｐ５３和ＢＣＬ－２两种基因的表达。结果为突变型Ｐ５３在原发和复发性膀胱癌中阳性表达率相近为２８．０７％（１６／５７）但在同一个体中７３％的病人原发和复发肿瘤中表达不相同。ＢＣＬ－２阳性表达率为８．８％（５／５７）。提示Ｐ５３阳性是膀胱肿瘤晚期或预后不良的一种现象，有效的手术可改善其预后。ＢＣＬ－２主要在复发肿瘤且应用化疗药物后病人中表达。可能与肿瘤对化疗药物产生耐药有关。
Using S-P immunohistochemistry technique, 57 paraffin-embedded tissue blocks from 38 patients with primary and recurring bladder transitional cell carcinoma were examined (24 patients with recurrence of more than two times, 9 patients with 5 years of non-recurrence, metastasis or Expression of mutant P53 and BCL-2 genes in 5 cases of death. As a result, the positive expression rate of mutant P53 in primary and recurrent bladder cancer was similar to 28.07% (16/57), but in the same individual 73% of patients had different expressions in primary and recurrent tumors. The positive rate of BCL-2 was 8.8% (5/57). It is suggested that P53 positive is a phenomenon of late or poor prognosis of bladder cancer, and effective surgery can improve its prognosis. BCL-2 is mainly expressed in patients with recurrent tumors and chemotherapeutic agents. It may be related to tumor resistance to chemotherapy drugs.